Sonic Healthcare Ltd (SHL)
Australian Securities Exchange · Australia · prices in AUD · close of 23 Oct 2026
Key indicators
| Last close | AUD 18.89 |
|---|---|
| 52-week range | 18.11 – 24.27 |
| Return, 1 month / 3 months | −0.6% / −6.2% |
| Return, 1 year / 3 years | −8.1% / −27.0% |
| Trend | Below its 200-day average |
| RSI (14) | 50 |
| Volatility (1 year) | 25.6% |
| Worst drawdown (1 year) | -21.4% |
| Average daily value traded | 60.90M AUD |
| Dividend yield | 5.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sonic Healthcare is a medical diagnostics company based in Australia. It runs pathology laboratories that analyse blood and tissue samples for doctors and hospitals, and it provides radiology services such as imaging scans. The company also offers clinical and administrative support to medical practices. Its customers are mainly general practitioners, specialists, hospitals and other healthcare providers who rely on its testing and diagnostic services in the countries where it operates.
The shares are listed on the Australian Securities Exchange in Australia under the code SHL, and the price on this page is in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sonic Healthcare Ltd (SHL) trades on the Australian Securities Exchange in Australia. It last closed at AUD 18.89 on 23 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 222 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 8.1% and over the last three months it fell 6.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 69 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -5.6% | ||
| From 52-week high | -20.8% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -6.2% | ||
| 6-month return | -3.3% | ||
| 12-month return, skipping the last month | -7.5% | ||
| Stability (higher is calmer) | 90 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 25.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.4% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 60.90M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | 58 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.7% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +1.7% |
|---|---|
| 1 month | −0.6% |
| 3 months | −6.2% |
| 6 months | −3.3% |
| 1 year | −8.1% |
| 3 years | −27.0% |
| 5 years | −42.1% |
Signals
| 50-day / 200-day average | 19.31 / 20.01 |
|---|---|
| Golden / death cross (60 days) | Death, 18 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.34 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Sep 2026 | AUD 0.6300 |
| 4 Mar 2026 | AUD 0.4500 |
| 3 Sep 2025 | AUD 0.6300 |
| 5 Mar 2025 | AUD 0.4400 |
| 4 Sep 2024 | AUD 0.6300 |
| 1 Mar 2024 | AUD 0.4300 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.